Logo
faq question Joey Med

GLP-1s and Heart Failure in 2026: New Research Shows the Benefits Go Beyond the Scale

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
New 2026 studies show GLP-1s like semaglutide and tirzepatide may improve heart pressures and function in people with obesity and heart failure — and cut hospital visits. What patients should know.

New 2026 studies show GLP-1s like semaglutide and tirzepatide may improve heart pressures and function in people with obesity and heart failure — and cut hospital visits. What patients should know.

Overview

For years, the story of GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) has been told in pounds lost. This month, cardiologists added a new chapter. In the span of about a week — at the American Heart Association's Scientific Sessions in Chicago and then at ObesityWeek 2026 in Washington — researchers presented data suggesting these drugs don't just shrink waistlines in people with obesity and heart failure. They may actually improve the heart's pressures, structure, and function, and in one randomized trial, more than half of treated patients went into heart failure remission. Here's what the new research found, where the evidence is strong and where it's still thin, and what it means if you're weighing GLP-1 treatment.

A Trial Where Hearts Measurably Improved

The most striking result came from a Mayo Clinic randomized trial published in Nature Medicine and presented at the AHA meeting. Researchers gave 81 adults with obesity and heart failure with preserved ejection fraction — the common form where the heart muscle pumps normally but has become stiff and fills poorly, often called HFpEF — either semaglutide or a placebo for 52 weeks.

As Reuters reported, semaglutide improved the pressures inside the heart both at rest and during exercise — the central problem in HFpEF, and the reason patients feel breathless climbing stairs or carrying groceries. Even more notable: treatment was associated with remission of heart failure in more than half of the patients who received the drug.

This builds on the landmark STEP-HFpEF trial published in the New England Journal of Medicine in 2023, which first showed semaglutide improved symptoms and physical function in this group. The new trial goes a step further by directly measuring what's happening inside the heart.

New Data in the Harder Cases, Too

A second Mayo Clinic study, presented at ObesityWeek 2026, looked at the other major form of the disease: heart failure with reduced ejection fraction, where the heart muscle itself is weakened. Researchers compared 146 patients with obesity who were taking semaglutide or tirzepatide against 237 closely matched patients who weren't.

After one year, the GLP-1 group showed significantly greater improvements in the left ventricle's size, shape, structure, and function — along with greater weight loss. Exploratory two-year analyses showed the improvements in ejection fraction and heart size continued, and most of the gains remained significant even after adjusting for how much weight patients lost, hinting that the drugs may help the heart through more than weight reduction alone.

One honest caveat: this was an observational study, not a randomized trial. And a separate meta-analysis presented at AHA 2026 — covered by MedCentral — pooled 14 randomized trial analyses with more than 30,000 patients and found the clearest wins in HFpEF, with no significant benefit in reduced ejection fraction. In preserved ejection fraction, that analysis found a 41% reduction in worsening heart failure events, a 31% reduction in worsening heart failure or cardiovascular death, a 7.4-point gain on a standard symptom score, and about 17.6 meters more on the six-minute walk test. So the strongest evidence today is for HFpEF; the reduced-EF findings are promising but not yet proof.

Fewer Hospital Visits — and Lower Downstream Costs

The same Reuters roundup included real-world economics data from Eli Lilly presented at ObesityWeek: more than 171,000 adults without diabetes treated with Zepbound for at least a year were compared with the same number of similar untreated people. Healthcare costs stayed stable in the Zepbound group while rising in the untreated group — by an estimated $29 per month at 3–6 months, $82 at 6–12 months, and $120 at 12–18 months. Zepbound patients also had 7% fewer hospitalizations and emergency visits at 3–6 months, 18% fewer through 12 months, and 34% fewer at 12–18 months.

Worth keeping in perspective: that analysis came from the drug's manufacturer, didn't report what patients themselves paid, and Zepbound can still cost more than $1,000 a month without insurance. A separate CVS Health study cited in the same report estimated employers could break even if GLP-1s were priced below $350 per month — a reminder that pricing, not science, is now the biggest barrier for many patients.

There was even a signal in older adults beyond the heart: a two-year study of more than 122,000 patients aged 65 and up found GLP-1 use was associated with a 13% lower risk of falls and a 37% lower risk of new wheelchair dependence compared with metformin — though the study couldn't prove the drugs caused those benefits.

What This Means If You're Considering a GLP-1

If you have obesity and have been told you have heart failure — especially the preserved ejection fraction kind — this research is a genuine reason for hope, and worth raising with your cardiologist. GLP-1s are not a replacement for your heart medications, and no one should start, stop, or switch treatment based on a headline. Heart failure care requires coordination between your prescribing provider and your cardiology team.

If you don't have heart failure but carry extra weight, the takeaway is different but just as real: the health case for treating obesity keeps getting stronger. Weight loss with GLP-1 medications improves blood pressure, blood sugar, and sleep apnea, and this year's data suggests the heart itself may benefit.

The medications still demand respect. Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose increases — manageable for most people, and anti-nausea support can help. GLP-1s aren't appropriate for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and anyone with a history of pancreatitis or significant gastrointestinal disease needs individualized guidance. That's why screening with a licensed provider matters.

How to Get Started With JoeyMed

If you've been thinking about treating your weight for the sake of your long-term health, JoeyMed makes the first step simple. A licensed provider reviews your health history — including any heart conditions and current medications — and determines whether treatment like compounded tirzepatide is appropriate for you, with ongoing follow-up as your dose changes.

Start your online visit at joeymed.com/weight-loss today. Your heart may thank you for it.

GLP-1s and Heart Failure in 2026: New Research Shows the Benefits Go Beyond the Scale | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL